ZAI Lab

OverviewSuggest Edit

Zai Lab is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for cancer, autoimmune and infectious diseases. It offers Zejula, a selective small-molecule poly (ADP-ribose) PARP 1/2inhibitor; Optune, a portable device that delivers tumor treating fields; and Qinlock, a switch-control tyrosine kinase inhibitor.
TypePublic
Founded2014
HQShanghai, CN
Websitezailaboratory.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Apr 2022)1,194
Job Openings50
Revenue (FY, 2021)$144.3 M(+195%)
Share Price (May 2022)$33.2(+23%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at ZAI Lab

Samantha Du

Samantha Du

Founder, Chair and Chief Executive Officer
Harald Reinhart

Harald Reinhart

Chief Medical Officer, Autoimmune and Infectious Diseases
Billy Cho

Billy Cho

Chief Financial Officer
F. Ty Edmondson

F. Ty Edmondson

Chief Legal Officer
William Liang

William Liang

Chief Commercial Officer, President, Greater China
Tao Fu

Tao Fu

Chief Strategy Officer
Show more

ZAI Lab Office Locations

ZAI Lab has offices in Shanghai, Beijing, Suzhou, Cambridge and in 3 other locations
Shanghai, CN (HQ)
4560 Jinke Road
Beijing, CN
22 Xidawang Road
Suzhou, CN
218 Sangtian Street
Hong Kong, HK
510 King's Road
Taipei, TW
Sec. 1, Keelung Road
Cambridge, MA, US
245 Main St 2nd floor
Show all (7)

ZAI Lab Financials and Metrics

ZAI Lab Revenue

ZAI Lab's revenue was reported to be $144.31 m in FY, 2021
USD

Revenue (FY, 2021)

144.3m

Gross profit (FY, 2021)

99.9m

Net income (FY, 2021)

(703.4m)

EBITDA (FY, 2021)

(692.2m)

EBIT (FY, 2021)

(704.2m)

Market capitalization (13-May-2022)

3.4b

Closing stock price (13-May-2022)

33.2

Cash (31-Dec-2021)

964.1m

EV

2.4b
ZAI Lab's current market capitalization is $3.4 b.
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

129.0k13.0m49.0m144.3m

Cost of goods sold

(44.0k)(3.7m)(12.1m)(44.4m)

Gross profit

85.0k9.2m36.9m99.9m

R&D expense

(118.6m)(138.5m)(222.7m)(573.3m)
Half Year
USDH1, 2020

Revenue

19.2m

Cost of goods sold

(5.0m)

Gross profit

14.2m

R&D expense

(102.0m)
Quarterly
USDQ1, 2019Q2, 2019Q1, 2021Q2, 2021Q3, 2021

Revenue

3.4m8.3m20.1m36.9m43.1m

Cost of goods sold

(882.0k)(2.2m)(6.1m)(9.3m)(10.5m)

Gross profit

2.5m6.2m14.0m27.6m32.6m

R&D expense

(58.9m)(107.6m)(203.9m)(142.2m)(55.1m)
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Cash

63.0m75.9m442.1m964.1m

Accounts Receivable

89.0k3.8m5.2m47.5m

Prepaid Expenses

5.7m6.7m10.9m18.0m

Inventories

4.0k6.0m13.1m19.0m
Half Year
USDH1, 2020

Cash

258.6m

Accounts Receivable

7.0m

Prepaid Expenses

7.7m

Inventories

6.6m
Quarterly
USDQ1, 2019Q2, 2019Q1, 2021Q2, 2021Q3, 2021

Cash

91.6m68.7m1.0b1.8b1.4b

Accounts Receivable

2.5m3.9m8.8m18.0m21.0m

Prepaid Expenses

6.0m4.2m14.3m12.9m17.1m

Inventories

141.0k890.0k12.6m11.1m12.5m
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(139.1m)(195.1m)(268.9m)(704.5m)

Depreciation and Amortization

1.6m3.8m4.6m6.5m

Inventories

(4.0k)(6.0m)(7.2m)(7.2m)

Accounts Payable

28.5m(14.8m)40.0m63.5m
Half Year
USDH1, 2020

Net Income

(128.6m)

Depreciation and Amortization

2.1m

Inventories

(571.0k)

Accounts Payable

9.7m
Quarterly
USDQ1, 2019Q2, 2019Q1, 2021Q2, 2021Q3, 2021

Net Income

(148.6m)(232.9m)(396.2m)(492.6m)

Depreciation and Amortization

2.5m1.4m3.0m4.6m

Inventories

502.0k1.7m248.0k

Accounts Payable

(21.2m)63.0m(11.2m)
Show all financial metrics

ZAI Lab Revenue Breakdown

Embed Graph

ZAI Lab revenue breakdown by business segment: 64.9% from ZEJULA, 27.0% from OPTUNE, 8.1% from QINLOCK and 0.0% from Other

ZAI Lab Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

ZAI Lab Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

ZAI Lab Online and Social Media Presence

Embed Graph

ZAI Lab News and Updates

Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass. and SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Zai Lab (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, and Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision o…

Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company’s Independent Registered Public Accounting Firm

Zai Lab’s engagement of an audit firm located in the United States is expected to facilitate the Company’s continued listing on Nasdaq because KPMG is subject to inspection by the PCAOB Zai Lab’s engagement of an audit firm located in the United States is expected to facilitate the Company’s continu…

Zai Lab Plants a Tree for Every Employee on Earth Day 2022

Partners with One Tree Planted and Donates at least $25,000 Partners with One Tree Planted and Donates at least $25,000

Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting

-  First preview of preclinical data for ZL-1218, an anti-CCR8 antibody, in an oral presentation

ZLAB EQUITY NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation – ZLAB

NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB) resulting from allegations that Zai Lab may have issued materially misleading b…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
Show more

ZAI Lab Frequently Asked Questions

  • When was ZAI Lab founded?

    ZAI Lab was founded in 2014.

  • Who are ZAI Lab key executives?

    ZAI Lab's key executives are Samantha Du, Harald Reinhart and Billy Cho.

  • How many employees does ZAI Lab have?

    ZAI Lab has 1,194 employees.

  • What is ZAI Lab revenue?

    Latest ZAI Lab annual revenue is $144.3 m.

  • What is ZAI Lab revenue per employee?

    Latest ZAI Lab revenue per employee is $120.9 k.

  • Who are ZAI Lab competitors?

    Competitors of ZAI Lab include Amoy Diagnostics, BGI Genomics and Berry Genomics.

  • Where is ZAI Lab headquarters?

    ZAI Lab headquarters is located at 4560 Jinke Road, Shanghai.

  • Where are ZAI Lab offices?

    ZAI Lab has offices in Shanghai, Beijing, Suzhou, Cambridge and in 3 other locations.

  • How many offices does ZAI Lab have?

    ZAI Lab has 7 offices.